Fulcrum Therapeutics, Inc. (FULC) shareholders
Close on Nov 17, 2026Market cap $286.12MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Tang Capital Management, LLC Joint filing with Kevin Tang (10.40%) | 6,913,329 | 10.40% | 13G (passive) amendment | Jul 13, 2026 |
| BlackRock Portfolio Management LLC | 6,155,437 | 8.10% | 13G (passive) amendment | Sep 30, 2026 |
| RA Capital Management, L.P. Joint filing with Peter Kolchinsky (11.20%), Rajeev Shah (11.20%) and 1 more | 6,053,960 | 11.20% | 13G (passive) amendment | Dec 8, 2025 |
| Oleg Nodelman Joint filing with EcoR1 Capital, LLC (9.00%), EcoR1 Capital Fund Qualified, L.P. (8.40%) | 6,000,000 | 9.00% | 13G (passive) | Jun 17, 2026 |
| Nantahala Capital Management, LLC Joint filing with Wilmot B. Harkey (8.22%), Daniel Mack (8.22%) | 5,475,040 | 8.22% | 13G (passive) | Jun 30, 2026 |
| Kevin Tang Joint filing with Tang Capital Management, LLC (8.20%) | 5,451,800 | 8.20% | 13G (passive) | Jun 3, 2026 |
| Suvretta Capital Management, LLC Joint filing with Aaron Cowen (9.40%), Averill Master Fund, Ltd. (8.60%) | 5,067,394 | 9.40% | 13G (passive) amendment | Mar 31, 2025 |
| BlackRock, Inc. | 4,802,880 | 7.20% | 13G (passive) amendment | Jun 30, 2026 |
| Adage Capital Management, L.P. Joint filing with Robert Atchinson (8.50%), Phillip Gross (8.50%) | 4,589,000 | 8.50% | 13G (passive) amendment | Jun 30, 2025 |
| Montanova Capital, LLC Joint filing with Aaron Cowen (5.50%) | 3,680,921 | 5.50% | 13G (passive) amendment | Jun 30, 2026 |
| Robert Atchinson Joint filing with Adage Capital Management, L.P. (5.56%), Phillip Gross (5.56%) | 3,000,000 | 5.56% | 13G (passive) | Dec 31, 2024 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of FULC | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Nantahala Capital Management, LLC | 10,950,080 | 14.35% | $40.08M | +7,900,040 | 0.67% |
| BlackRock, Inc. | 8,824,259 | 11.57% | $32.30M | +3,433,666 | 0.00% |
| EcoR1 Capital, LLC | 6,549,866 | 8.58% | $23.97M | New | 1.17% |
| Tang Capital Management LLC | 6,521,412 | 8.55% | $23.87M | New | 1.08% |
| Suvretta Capital Management, LLC | 3,680,921 | 4.82% | $13.47M | −2,880,190 | 0.25% |
| D. E. Shaw & Co., Inc. | 3,044,385 | 3.99% | $11.14M | +1,421,104 | 0.01% |
| Citadel Advisors LLC | 2,704,505 | 3.54% | $9.90M | +1,412,019 | 0.00% |
| Vanguard Capital Management LLC | 2,697,216 | 3.54% | $9.87M | +4,268 | 0.00% |
| Jane Street Group, LLC | 2,217,498 | 2.91% | $8.12M | +1,907,081 | 0.00% |
| State Street Corp | 2,037,025 | 2.67% | $7.46M | +487,174 | 0.00% |
| Adage Capital Partners Gp, L.L.C. | 2,000,000 | 2.62% | $7.32M | +1,600,000 | 0.01% |
| GSK plc | 1,785,714 | 2.34% | $6.54M | – | 1.09% |
| Qube Research & Technologies Ltd | 1,748,467 | 2.29% | $6.40M | +773,728 | 0.01% |
| Assenagon Asset Management S.A. | 1,670,408 | 2.19% | $6.11M | +476,535 | 0.00% |
| Renaissance Technologies LLC | 1,647,800 | 2.16% | $6.03M | +1,634,200 | 0.01% |
| ADAR1 Capital Management, LLC | 1,565,029 | 2.05% | $5.73M | +1,434,469 | 0.26% |
| Millennium Management LLC | 1,485,803 | 1.95% | $5.44M | +1,129,332 | 0.00% |
| Geode Capital Management, LLC | 1,432,133 | 1.88% | $5.24M | −54,409 | 0.00% |
| Marshall Wace, Llp | 1,358,423 | 1.78% | $4.97M | New | 0.00% |
| UBS Group AG | 1,253,909 | 1.64% | $4.59M | +938,724 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 155 | 86M | 100.0% | 29 / 73 | 34 / 42 | 47M | 33M |
| Q1 2026 | 169 | 72M | 94.0% | 37 / 73 | 39 / 38 | 17M | 10M |
| Q4 2025 | 172 | 68M | 88.6% | 59 / 44 | 49 / 16 | 23M | 10M |
| Q3 2025 | 129 | 54M | 70.5% | 26 / 41 | 42 / 18 | 7M | 7M |
| Q2 2025 | 122 | 54M | 71.3% | 24 / 34 | 46 / 19 | 7M | 4M |
| Q1 2025 | 117 | 51M | 67.3% | 18 / 32 | 42 / 19 | 4M | 5M |
| Q4 2024 | 119 | 52M | 68.1% | 24 / 33 | 40 / 33 | 8M | 11M |
| Q3 2024 | 130 | 55M | 72.2% | 44 / 31 | 35 / 34 | 24M | 29M |
| Q2 2024 | 121 | 65M | 85.0% | 31 / 45 | 26 / 36 | 12M | 10M |
| Q1 2024 | 126 | 63M | 82.4% | 36 / 34 | 28 / 11 | 8M | 8M |
| Q4 2023 | 101 | 62M | 81.7% | 31 / 24 | 21 / 11 | 11M | 6M |
| Q3 2023 | 81 | 57M | 74.2% | 15 / 17 | 26 / 21 | 7M | 5M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
154 funds held FULC in Q2 2026, 65% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of FULC | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2,074,332 | 2.72% | $7.59M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 1,552,712 | 2.04% | $5.68M | 0.01% | Jun 30, 2026 |
| State Street(R) SPDR(R) S&P(R) Pharmaceuticals ETF | 807,587 | 1.06% | $2.96M | 0.69% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 646,379 | 0.85% | $2.31M | 0.01% | Jul 31, 2026 |
| iShares Russell 2000 Value ETF | 567,824 | 0.74% | $2.08M | 0.01% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 553,375 | 0.73% | $2.03M | 0.00% | Jun 30, 2026 |
| BlackRock Advantage Small Cap Core Fund | 416,770 | 0.55% | $2.88M | 0.05% | May 29, 2026 |
| iShares Biotechnology ETF | 398,072 | 0.52% | $1.46M | 0.02% | Jun 30, 2026 |
| Vanguard Russell 2000 Index Fund | 306,585 | 0.40% | $2.12M | 0.01% | May 31, 2026 |
| Fidelity Extended Market Index Fund | 251,883 | 0.33% | $1.74M | 0.00% | May 31, 2026 |
| Schwab U.S. Small-Cap ETF | 228,499 | 0.30% | $1.58M | 0.01% | May 31, 2026 |
| iShares Micro-Cap ETF | 199,458 | 0.26% | $730.02K | 0.05% | Jun 30, 2026 |
| U.S. Micro Cap Portfolio | 168,604 | 0.22% | $603.60K | 0.01% | Jul 31, 2026 |
| Vanguard Strategic Small-Cap Equity Fund | 162,121 | 0.21% | $593.36K | 0.02% | Jun 30, 2026 |
| U.S. Small Cap Portfolio | 157,099 | 0.21% | $562.41K | 0.00% | Jul 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Alex Sapir | See Remarks, Director | 193,360 | 0.25% | Feb 4, 2026 |
| Alan A. Musso | Chief Financial Officer | 0 | – | Feb 4, 2026 |
| Greg Tourangeau | Principal Accounting Officer | 14,062 | 0.02% | Feb 4, 2026 |
| Curtis Gale Oltmans | Chief Legal Officer | 10,252 | 0.01% | Feb 4, 2026 |
| Alan Ezekowitz | Director | 10,927 | 0.01% | Jul 2, 2026 |
| James A. Geraghty | Director | 90,714 | 0.12% | Jul 2, 2026 |
| Katina Dorton | Director | 0 | – | Jul 2, 2026 |
| Robert J. Gould | Director | 454,864 | 0.60% | Jul 2, 2026 |
| Kate Haviland | Director | – | – | Jul 2, 2026 |
| Colin Hill | Director | 0 | – | Jul 2, 2026 |
| Sonja Banks | Director | 0 | – | Jul 2, 2026 |
| Rachel K. King | Director | – | – | Jul 2, 2026 |
| Joshua Lehrer-Graiwer | Director | 0 | – | May 1, 2026 |
| Kevin Tang | 10% owner | 7,080,945 | 9.28% | Jul 20, 2026 |
| Capital Management Llc Tang | 10% owner | 6,913,329 | 9.06% | Jul 20, 2026 |
| Peter Kolchinsky | 10% owner | 9,505,925 | 12.46% | Dec 10, 2025 |
| Rajeev M. Shah | 10% owner | 3,109,704 | 4.08% | Dec 10, 2025 |
| Capital Healthcare Fund LP RA | 10% owner | 6,145,682 | 8.05% | Dec 10, 2025 |
| Ra Capital Management, L.P. | 10% owner | 10,229,099 | 13.41% | Dec 10, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Kevin Tang 10% owner | Jul 17, 2026 | Buy | +50,945 | $3.52 | $179.33K | 7,080,945 |
| Kevin Tang 10% owner | Jul 16, 2026 | Buy | +116,671 | $3.56 | $415.35K | 7,030,000 |
| Capital Management Llc Tang 10% owner | Jul 15, 2026 | Buy | +107,377 | $3.56 | $382.26K | 6,913,329 |
| Capital Management Llc Tang 10% owner | Jul 14, 2026 | Buy | +53,651 | $3.56 | $191.00K | 6,730,000 |
| Capital Management Llc Tang 10% owner | Jul 14, 2026 | Buy | +75,952 | $3.58 | $271.91K | 6,805,952 |
| Capital Management Llc Tang 10% owner | Jul 13, 2026 | Buy | +12,966 | $3.54 | $45.90K | 6,676,349 |
| Alan Ezekowitz Director | Jun 26, 2026 | Sale(10b5-1 plan) | −18,000 | $3.65 | $65.70K | 10,927 |
| Robert J. Gould Director | Feb 2, 2026 | Sale(10b5-1 plan) | −15,000 | $10.72 | $160.80K | 454,864 |
| Robert J. Gould Director | Jan 2, 2026 | Sale(10b5-1 plan) | −15,000 | $10.87 | $163.05K | 469,864 |
| Robert J. Gould Director | Jan 2, 2026 | Sale(10b5-1 plan) | −15,000 | $11.87 | $178.05K | 469,864 |
| Curtis Gale Oltmans Chief Legal Officer | Dec 15, 2025 | Sale(10b5-1 plan) | −3,452 | $12.92 | $44.60K | 10,252 |
| Capital Healthcare Fund LP RA 10% owner | Dec 8, 2025 | Sale | −2,706,397 | $14.28 | $38.65M | 6,145,682 |
| Capital Healthcare Fund LP RA 10% owner | Dec 8, 2025 | Sale | −91,722 | $14.98 | $1.37M | 6,053,960 |
| Capital Healthcare Fund LP RA 10% owner | Dec 8, 2025 | Sale | −1,377,020 | $13.33 | $18.36M | 8,852,079 |
| Robert J. Gould Director | Nov 19, 2025 | Sale(10b5-1 plan) | −15,000 | $11.03 | $165.45K | 484,864 |
| Greg Tourangeau Principal Accounting Officer | May 8, 2025 | Sale | −498 | $5.06 | $2.52K | 14,062 |
| Rajeev M. Shah 10% owner | Aug 21, 2024 | Other | −8,500,000 | – | – | 3,109,704 |
| Alex Sapir See Remarks, Director | Jul 3, 2024 | Option exercise | +150,000 | $3.27 | $490.50K | 193,360 |
| Greg Tourangeau Principal Accounting Officer | May 7, 2024 | Sale | −236 | $7.76 | $1.83K | 11,571 |
| Greg Tourangeau Vice President, Finance | Mar 8, 2024 | Sale | −4,884 | $11.72 | $57.24K | 11,807 |
| Alex Sapir See Remarks, Director | Mar 4, 2024 | Buy | +43,360 | $11.35 | $492.14K | 43,360 |
| Greg Tourangeau Principal Accounting Officer | May 10, 2023 | Sale | −210 | $3.31 | $695 | 15,992 |
| Ra Capital Management, L.P. 10% owner | Jan 20, 2023 | Buy | +1,923,076 | $13.00 | $25.00M | 11,609,704 |
| Robert J. Gould Interim President & CEO, Director | Jan 13, 2023 | Sale(10b5-1 plan) | −6,766 | $15.00 | $101.49K | 499,864 |
| Capital Healthcare Fund LP RA 10% owner | Jan 4, 2023 | Buy | +122,334 | $7.03 | $860.01K | 9,628,259 |
| Capital Healthcare Fund LP RA 10% owner | Jan 4, 2023 | Buy | +58,369 | $7.80 | $455.28K | 9,686,628 |
| Peter Kolchinsky 10% owner | Dec 27, 2022 | Buy | +4,089 | $5.99 | $24.49K | 9,505,925 |
| Peter Kolchinsky 10% owner | Dec 19, 2022 | Buy | +98,787 | $5.90 | $582.84K | 9,501,836 |
| Ra Capital Management, L.P. 10% owner | Dec 16, 2022 | Buy | +1,341,420 | $5.42 | $7.27M | 9,403,049 |
| Ra Capital Management, L.P. 10% owner | Dec 15, 2022 | Buy | +237,029 | $5.50 | $1.30M | 8,061,629 |
| Ra Capital Management, L.P. 10% owner | Dec 14, 2022 | Buy | +824,600 | $5.46 | $4.50M | 7,824,600 |
| Trv Gp Iii, Llc 10% owner | Dec 13, 2022 | Other | −2,000,000 | – | – | 1,962,202 |
| Robert J. Gould Director | Jun 7, 2022 | Option exercise | +71,435 | $7.84 | $560.05K | 578,065 |
| Robert J. Gould Director | Jun 7, 2022 | Sale(10b5-1 plan) | −71,435 | $8.09 | $577.91K | 506,630 |
| Robert J. Gould Director | Jun 6, 2022 | Option exercise | +24,382 | $7.84 | $191.15K | 531,012 |
| Robert J. Gould Director | Jun 6, 2022 | Sale(10b5-1 plan) | −24,382 | $8.10 | $197.49K | 506,630 |
| Robert J. Gould Director | Jun 3, 2022 | Option exercise | +25,551 | $7.84 | $200.32K | 532,181 |
| Robert J. Gould Director | Jun 3, 2022 | Sale(10b5-1 plan) | −25,551 | $7.95 | $203.13K | 506,630 |
| Robert J. Gould Director | Jun 2, 2022 | Option exercise | +16,689 | $7.84 | $130.84K | 523,319 |
| Robert J. Gould Director | Jun 2, 2022 | Sale(10b5-1 plan) | −16,689 | $7.92 | $132.18K | 506,630 |
| Greg Tourangeau Controller | May 6, 2022 | Award | +3,250 | – | – | 16,202 |
| Robert J. Gould Director | Apr 7, 2022 | Option exercise | +5,631 | $7.84 | $44.15K | 512,261 |
| Robert J. Gould Director | Apr 7, 2022 | Sale(10b5-1 plan) | −5,631 | $24.02 | $135.26K | 506,630 |
| Robert J. Gould Director | Apr 5, 2022 | Option exercise | +52,552 | $7.84 | $412.01K | 559,182 |
| Robert J. Gould Director | Apr 5, 2022 | Sale(10b5-1 plan) | −52,552 | $24.26 | $1.27M | 506,630 |
| Robert J. Gould Director | Apr 4, 2022 | Option exercise | +7,235 | $7.84 | $56.72K | 513,865 |
| Robert J. Gould Director | Apr 4, 2022 | Sale(10b5-1 plan) | −7,235 | $24.02 | $173.78K | 506,630 |
| Robert J. Gould Director | Apr 1, 2022 | Sale(10b5-1 plan) | −34,464 | $24.03 | $828.17K | 506,630 |
| Robert J. Gould Director | Apr 1, 2022 | Option exercise | +34,464 | $7.84 | $270.20K | 541,094 |
| Curtis Gale Oltmans SVP, General Counsel | Dec 17, 2021 | Gift | −1,088 | – | – | 1,248 |
| Mark J. Levin Director, 10% owner | Nov 10, 2021 | Other | −1,000,000 | – | – | 3,962,202 |
| Kevin P. Starr 10% owner | Nov 10, 2021 | Other | −1,000,000 | – | – | 3,962,202 |
| Kevin P. Starr 10% owner | Sep 22, 2021 | Other | −1,000,000 | – | – | 4,962,202 |
| Mark J. Levin Director, 10% owner | Sep 22, 2021 | Other | −1,000,000 | – | – | 4,962,202 |
| Bryan Stuart See Remarks, Director | Aug 11, 2021 | Sale(10b5-1 plan) | −28,000 | $23.75 | $665.00K | 0 |
| Bryan Stuart See Remarks, Director | Aug 11, 2021 | Option exercise | +28,000 | $7.84 | $219.52K | 28,000 |
| Christopher Moxham Chief Scientific Officer | Aug 10, 2021 | Option exercise | +20,714 | $7.84 | $162.40K | 20,714 |
| Christopher Moxham Chief Scientific Officer | Aug 10, 2021 | Sale(10b5-1 plan) | −20,714 | $17.00 | $352.14K | 0 |
| Christopher Moxham Chief Scientific Officer | Aug 10, 2021 | Option exercise | +31,071 | $7.84 | $243.60K | 31,071 |
| Christopher Moxham Chief Scientific Officer | Aug 10, 2021 | Sale(10b5-1 plan) | −31,071 | $18.00 | $559.28K | 0 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Fulcrum Therapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 17,115 shares on Aug 20, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Greg Tourangeau former officer | Sep 2, 2026 | 14,062 | $54.42K | Sep 2, 2026 | Restricted Stock Awards |
| Alan Ezekowitz Director | Jun 26, 2026 | 18,000 | $64.98K | Jun 26, 2026 | Restricted Stock Units |
| Curtis Gale Oltmans Officer | Dec 15, 2025 | 3,452 | $44.88K | Dec 15, 2025 | Employee Stock Purchase Plan |
| Capital Healthcare Fund LP RA 10% Stockholder | Dec 8, 2025 | 4,175,139 | $54.24M | Dec 8, 2025 | Secondary |
| Robert J. Gould Director | Nov 19, 2025 | 45,000 | $437.85K | Nov 19, 2025 | Founders Shares |
| Greg Tourangeau Officer | Mar 8, 2024 | 4,884 | $57.22K | Mar 8, 2024 | Stock option exercises |
See a number that looks wrong?